Abstracts tagged "glucocorticoids"

Abstract Number: 2339 • 2018 ACR/ARHP Annual Meeting
The Patient’s Perspective of Glucocorticoid Use: A Systematic Literature Review of Quantitative and Qualitative Studies
Jonathan Cheah^1,2, Joanna Robson^3,4, Rachel Black^5,6, Susan M. Goodman^7,8, Susan Lester^9,10, Sarah Mackie¹¹ and Catherine Hill^6,12, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Medicine, Weill Cornell Medicine, New York, NY, ³Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ⁴School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁵Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁶Medicine, The University of Adelaide, Adelaide, Australia, ⁷Rheumatology, Weill Cornell Medicine, New York, NY, ⁸Hospital for Special Surgery, New York, NY, ⁹Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia, ¹⁰Discipline of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, ¹¹NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ¹²The Queen Elizabeth Hospital, Adelaide, Australia
Background/Purpose: Glucocorticoids (GCs) remain widely used and have well documented adverse effects. However, the impact of these adverse effects from the perspective of the patient,…
Abstract Number: 2654 • 2017 ACR/ARHP Annual Meeting
Treatment-Associated DNA Methylation Patterns in Systemic Lupus Erythematosus
Juliana Imgenberg-Kreuz^1,2, Jonas Carlsson Almlöf¹, Dag Leonard³, Gunnel Nordmark², Maija-Leena Eloranta³, Leonid Padyukov⁴, Iva Gunnarsson⁴, Elisabet Svenungsson⁴, Christopher Sjöwall⁵, Lars Rönnblom², Ann-Christine Syvänen¹ and Johanna K Sandling^1,2, ¹Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ³Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ⁴Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping University, Linköping, Sweden, Linköping, Sweden
Background/Purpose: DNA methylation has emerged as an important contributing factor in the pathogenesis of systemic lupus erythematosus (SLE). SLE typically requires continuous treatment to control…
Abstract Number: 212 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Large Vessel Arteritis (Giant Cell Arteritis and Temporal Arteritis): Findings from a Large Contemporaneous Real-World Cohort in the US
Zhaohui Su¹, Vandana Menon¹, Richard Gliklich² and Tom Brecht¹, ¹Research, OM1, Inc, Cambridge, MA, ²OM1, Inc, Cambridge, MA
Background/Purpose: Giant cell arteritis (GCA) is the most common form of primary systemic vasculitis with annual incidence as high as 27 per 100,000 in persons…
Abstract Number: 793 • 2017 ACR/ARHP Annual Meeting
Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be
Ignacio Castaño¹, Irene Monjo², Alejandro Balsa³, Diana Peiteado², Sara García-Carazo⁴ and Eugenio De Miguel¹, ¹Medicine, Universidad Autonoma Madrid, MADRID, Spain, ²Rheumatology, Hospital Universitario La Paz, MADRID, Spain, ³Rheumatology, Hospital La Paz-IdiPAZ, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: The high-dose glucocorticoids (GCs) are the mainstay of treatment in Giant Cell Arteritis (GCA). Patients treated with greater GC dosages are at the greatest…
Abstract Number: 804 • 2017 ACR/ARHP Annual Meeting
The Efficacy and Safety of the Anti-IL-6 Receptor Antibody Tocilizumab for Polymyalgia Rheumatica Patients with Resistance or Intolerance to Glucocorticoids and Methotrexate
Manami Hirata¹, Akiko Ueno², kazuyuki fujita², Nobuyuki Shibutou² and Masahiro Yamamura³, ¹Center for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ²Centor for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ³Okayama Saiseikai General Hospital, Okayama, Japan
Background/Purpose: Some patients show inadequate responses to initial glucocorticoids (GC) doses or relapses during GC tapering and develop side effects of GCs. The 2015 EULAR/ACR…
Abstract Number: 896 • 2017 ACR/ARHP Annual Meeting
The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: A Systematic Review and Meta-Analysis
Jennifer Rodrigues¹, David Collister¹, Amy Archer², Kim Cheema³, Paul Alexander⁴, Christian Pagnoux⁵, Lehana Thabane⁴, Peter A. Merkel⁶, David Jayne⁷ and Michael Walsh¹, ¹Nephrology, McMaster University, Hamilton, ON, Canada, ²Rheumatology, Northwestern University, Chicago, IL, ³Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses of ANCA-associated vasculitis (AAV) are associated with death, decreased renal function, and end-stage renal disease. Whether longer-term treatment with glucocorticoids (GC) reduces the…
Abstract Number: 1600 • 2017 ACR/ARHP Annual Meeting
Lupus Nephritis Is Associated with Increased Rates of Hospitalization for Adverse Events on a Glucocorticoid Toxicity Index and in-Hospital Mortality Compared with Non-Renal Lupus and Matched Controls: An Analysis of Insurance Claims Data
Katherine Belendiuk¹, Huong Trinh², Matthew Cascino¹, Leonard Dragone¹, Daniel Keebler¹, Jay Garg¹ and Paul Brunetta¹, ¹Genentech, Inc., South San Francisco, CA, ²Genentech, South San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is heterogeneous in its clinical prognosis and lupus nephritis (LN) is a major cause of morbidity and mortality among children…
Abstract Number: 1624 • 2017 ACR/ARHP Annual Meeting
SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Zahi Touma¹, Dafna D Gladman², Jiandong Su³, Nicole Anderson⁴ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) is one of the most commonly used disease activity indices in clinical practice and research but this…
Abstract Number: 2043 • 2017 ACR/ARHP Annual Meeting
Adherence to American College of Rheumatology Guidelines for Prevention of Glucocorticoid-Induced Osteoporosis in Patients with Polymyalgia Rheumatica
Brittany Frankel¹, Angela Christensen² and Monica Guma³, ¹Internal Medicine, University of California, San Diego, San Diego, CA, ²Rheumatology, University of California, San Diego, San Diego, CA, ³University of California, San Diego, San Diego, CA
Background/Purpose: American College of Rheumatology (ACR) 2010 guidelines recommend that any patient initiating glucocorticoid therapy with an anticipated duration of ≥3 months should receive a…
Abstract Number: 2279 • 2017 ACR/ARHP Annual Meeting
Dynamics of Concomitant Therapy in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Ekaterina Alexeeva^1,2, Tatiana Dvoryakovskaya^1,2, Victor Gladkikh^3,4, Andrei Moskalev^4,5, Rina Denisova², Ksenia Isaeva², Olga Lomakina², Margarita Soloshenko² and Anna Karaseva², ¹Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ²Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ³Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, ⁴Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, ⁵Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation
Background/Purpose: The effectiveness of target use of biological medications depends on how personalized they are to fit patient’s individual parameters with juvenile idiopathic arthritis (JIA).…
Abstract Number: 2367 • 2017 ACR/ARHP Annual Meeting
The Effect of Glucocorticoids on Bone Mineral Density in Patients with Rheumatoid Arthritis: a Systematic Review and Meta-Analysis
Anne-Birgitte Blavnsfeldt^1,2, Malissa Dawn Thomsen³, Simon Tarp⁴, Bente Langdahl^2,5, Ellen-Margrethe Hauge^2,6 and Annette de Thurah^7,8, ¹Rheumatology, Aarhus Universityhospital, Aarhus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark, ³Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, ⁴The Parker Institute, Bispebjerg & Frederiksberg Hospital, Copenhagen, Denmark, ⁵Endocrinology, Aarhus University Hospital, Aarhus, Denmark, ⁶Aarhus Universityhospital, Aarhus C, Denmark, ⁷Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ⁸Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: The role of glucocorticoids (GCs) in the treatment of rheumatoid arthritis (RA) is widely debated. GCs stimulate bone resorption and impair bone formation. Inflammatory…
Abstract Number: 1930 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis
Matthew D. Cascino¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁶, Cees G.M. Kallenberg⁷, E. William St Clair⁸, Paul A. Monach⁹, John H. Stone¹⁰ and Paul Brunetta¹¹, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Mayo Clinic, Rochester, MN, ³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Duke University Medical Center, Durham, NC, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹Genentech, Inc., South San Francisco, CA
Background/Purpose: Factors associated with cumulative glucocorticoid exposure in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) have not previously been described. We examined the association…
Abstract Number: 1973 • 2016 ACR/ARHP Annual Meeting
Intramuscular Versus Ultrasound Guided Peritendinous Glucocorticoid Injection for Tenosynovitis in Patients with Rheumatoid Arthritis – a Randomised, Double-Blind, Controlled Study
Mads Ammitzbøll-Danielsen^1,2, Mikkel Ostergaard^2,3, Viktoria Fana⁴, Daniel Glinatsi^2,5, Uffe Møller Døhn⁶, Lykke Midtbøll Ørnbjerg⁷, Esperanza Naredo⁸ and Lene Terslev⁶, ¹Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Rigshospitalet , Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁵Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁸Rheumatology, Hospital General Universitario Gregorio Marañón and Universidad Complutense, Madrid, Spain
Background/Purpose: The aim of this study was to compare the efficacy of intramuscular versus ultrasound (US)-guided peritendinous glucocorticoid injection in providing disease control after…
Abstract Number: 2477 • 2016 ACR/ARHP Annual Meeting
Short Term Clinical Response to Initial Treatment with High Versus Low Dose Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients
SA Bergstra¹, CF Allaart¹, R van den Berg¹, A Chopra², N Govind³, MJ Santos⁴, TWJ Huizinga⁵ and RBM Landewé^6,7, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Center for Rheumatic Diseases, Pune, India, Pune, India, ³Department of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, Johannesburg, South Africa, ⁴Rheumatology, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ⁵Leiden University Medical Centre, Leiden, Netherlands, ⁶Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands, ⁷Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of methotrexate (MTX) for newly diagnosed rheumatoid…
Abstract Number: 2547 • 2016 ACR/ARHP Annual Meeting
Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis
Frank Buttgereit¹, Jonna Amann², Friederike Breitenfeldt³, Dörte Huscher⁴, Johannes WJ Bijlsma⁵ and Johannes WG Jacobs⁶, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁴Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ⁵ARC, Amsterdam, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Glucocorticoids (GCs) are frequently and often chronically used for the treatment of rheumatoid arthritis (RA) and other immune diseases and vasculitis. An estimated 0.8–1.2%…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].